| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2005.03.4074 |
| P698 | PubMed publication ID | 16801630 |
| P2093 | author name string | A Robert MacLeod | |
| Frederic J Reu | |||
| Ernest C Borden | |||
| Normand Beaulieu | |||
| Daniel Lindner | |||
| Douglas W Leaman | |||
| Leonid Cherkassky | |||
| Soo In Bae | |||
| P2860 | cites work | Systematic variation in gene expression patterns in human cancer cell lines | Q28145747 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| renal carcinoma | Q18556333 | ||
| P304 | page(s) | 3771-3779 | |
| P577 | publication date | 2006-06-26 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation | |
| P478 | volume | 24 |
| Q53020638 | A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral blood containing gastric cancer-derived circulating tumor cells. |
| Q33415592 | A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations |
| Q36835008 | A potential predictive marker for response to interferon in malignant melanoma |
| Q34516587 | Aberrant DNA methylation in malignant melanoma |
| Q38574574 | Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations |
| Q39727366 | Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells |
| Q36906147 | Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma |
| Q34405013 | Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation |
| Q35132878 | Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine |
| Q34972245 | DNA demethylating antineoplastic strategies: a comparative point of view |
| Q33862334 | DNA hypomethylation in cancer cells |
| Q34646527 | Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex |
| Q33491820 | Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer |
| Q36801625 | Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. |
| Q36266756 | Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo |
| Q36129174 | Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding |
| Q37310619 | Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. |
| Q37707110 | Epigenetic therapy in urologic cancers: an update on clinical trials. |
| Q37531849 | Epigenetics in human melanoma |
| Q88985337 | Epigenetics in renal cell cancer: mechanisms and clinical applications |
| Q33980682 | Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies |
| Q35857807 | Epigenetics of kidney cancer and bladder cancer |
| Q38148588 | Epigenetics of melanoma: implications for immune-based therapies. |
| Q21131237 | Exploiting tumor epigenetics to improve oncolytic virotherapy |
| Q37854737 | Hypomethylating agents for urologic cancers |
| Q37302745 | IAP-targeted therapies for cancer |
| Q35815888 | IFNγ Induces DNA Methylation-Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer |
| Q37687572 | ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system |
| Q45996355 | Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. |
| Q48136845 | Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review. |
| Q28474843 | Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications |
| Q33988567 | Interferons and their stimulated genes in the tumor microenvironment |
| Q91212056 | Interferons α and β in cancer: therapeutic opportunities from new insights |
| Q36402715 | Irradiation affects cellular properties and Eph receptor expression in human melanoma cells |
| Q93015066 | LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling |
| Q35144877 | MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia |
| Q37524412 | Manipulating the epigenome for the treatment of urological malignancies |
| Q37301003 | Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside |
| Q64097726 | OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug |
| Q90860049 | Oncometabolites in renal cancer |
| Q37618815 | P2X7-mediated chemoprevention of epithelial cancers |
| Q34061112 | Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors |
| Q37730440 | Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy |
| Q34513042 | RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis. |
| Q37592077 | Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. |
| Q33598823 | Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2 |
| Q40102556 | Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. |
| Q26801268 | Role of DNA methylation in renal cell carcinoma |
| Q37147752 | Selective anticancer strategies via intervention of the death pathways relevant to cell transformation |
| Q26744089 | Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective |
| Q21260407 | Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta |
| Q58615651 | Stress and interferon signalling-mediated apoptosis contributes to pleiotropic anticancer responses induced by targeting NGLY1 |
| Q58801106 | Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells |
| Q55435258 | Targeting DNA Methyltranferases in Urological Tumors. |
| Q89510215 | Targeting the Immune system and Epigenetic Landscape of Urological Tumors |
| Q35037004 | The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy |
| Q88733594 | The Role of DNA Methylation in Renal Cell Carcinoma |
| Q39179082 | The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling |
| Q39540184 | Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis |
| Q38514782 | Tobacco carcinogen NNK-induced lung cancer animal models and associated carcinogenic mechanisms |
| Q36896195 | Tumor immunoediting and immunosculpting pathways to cancer progression. |
| Q39486541 | Type I IFNs signaling and apoptosis resistance in glioblastoma cells. |
| Q50326522 | X-linked inhibitor of apoptosis-associated factor 1 regulates TNF receptor 1 complex stability |
Search more.